A Canadian Adult Spinal Muscular Atrophy Outcome Measures Toolkit : Results of a National Consensus using a Modified Delphi Method
BACKGROUND: Spinal Muscular Atrophy (SMA) is a rare disease that affects 1 in 11 000 live births. Recent developments in SMA treatments have included new disease-modifying therapies that require high quality data to inform decisions around initiation and continuation of therapy. In Canada, there are no nationally agreed upon outcome measures (OM) used in adult SMA. Standardization of OM is essential to obtain high quality data that is comparable among neuromuscular clinics.
OBJECTIVE: To develop a recommended toolkit and timing of OM for assessment of adults with SMA.
METHODS: A modified delphi method consisting of 2 virtual voting rounds followed by a virtual conference was utilized with a panel of expert clinicians treating adult SMA across Canada.
RESULTS: A consensus-derived toolkit of 8 OM was developed across three domains of function, with an additional 3 optional measures. Optimal assessment frequency is 12 months for most patients regardless of therapeutic access, while patients in their first year of receiving disease-modifying therapy should be assessed more frequently.
CONCLUSIONS: The implementation of the consensus-derived OM toolkit will improve monitoring and assessment of adult SMA patients, and enrich the quality of real-world evidence. Regular updates to the toolkit must be considered as new evidence becomes available.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
|---|---|
| Enthalten in: |
Journal of neuromuscular diseases - 8(2021), 4 vom: 17., Seite 579-588 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Slayter, Jeremy [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adult spinal muscular atrophy |
|---|
| Anmerkungen: |
Date Completed 20.12.2021 Date Revised 20.12.2021 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.3233/JND-200617 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM32422026X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM32422026X | ||
| 003 | DE-627 | ||
| 005 | 20231225185843.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3233/JND-200617 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1080.xml |
| 035 | |a (DE-627)NLM32422026X | ||
| 035 | |a (NLM)33867362 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Slayter, Jeremy |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A Canadian Adult Spinal Muscular Atrophy Outcome Measures Toolkit |b Results of a National Consensus using a Modified Delphi Method |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.12.2021 | ||
| 500 | |a Date Revised 20.12.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: Spinal Muscular Atrophy (SMA) is a rare disease that affects 1 in 11 000 live births. Recent developments in SMA treatments have included new disease-modifying therapies that require high quality data to inform decisions around initiation and continuation of therapy. In Canada, there are no nationally agreed upon outcome measures (OM) used in adult SMA. Standardization of OM is essential to obtain high quality data that is comparable among neuromuscular clinics | ||
| 520 | |a OBJECTIVE: To develop a recommended toolkit and timing of OM for assessment of adults with SMA | ||
| 520 | |a METHODS: A modified delphi method consisting of 2 virtual voting rounds followed by a virtual conference was utilized with a panel of expert clinicians treating adult SMA across Canada | ||
| 520 | |a RESULTS: A consensus-derived toolkit of 8 OM was developed across three domains of function, with an additional 3 optional measures. Optimal assessment frequency is 12 months for most patients regardless of therapeutic access, while patients in their first year of receiving disease-modifying therapy should be assessed more frequently | ||
| 520 | |a CONCLUSIONS: The implementation of the consensus-derived OM toolkit will improve monitoring and assessment of adult SMA patients, and enrich the quality of real-world evidence. Regular updates to the toolkit must be considered as new evidence becomes available | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Adult spinal muscular atrophy | |
| 650 | 4 | |a consensus | |
| 650 | 4 | |a delphi method | |
| 650 | 4 | |a neuromuscular diseases | |
| 650 | 4 | |a outcome measures | |
| 700 | 1 | |a Hodgkinson, Victoria |e verfasserin |4 aut | |
| 700 | 1 | |a Lounsberry, Josh |e verfasserin |4 aut | |
| 700 | 1 | |a Brais, Bernard |e verfasserin |4 aut | |
| 700 | 1 | |a Chapman, Kristine |e verfasserin |4 aut | |
| 700 | 1 | |a Genge, Angela |e verfasserin |4 aut | |
| 700 | 1 | |a Izenberg, Aaron |e verfasserin |4 aut | |
| 700 | 1 | |a Johnston, Wendy |e verfasserin |4 aut | |
| 700 | 1 | |a Lochmüller, Hanns |e verfasserin |4 aut | |
| 700 | 1 | |a O'Ferrall, Erin |e verfasserin |4 aut | |
| 700 | 1 | |a Pfeffer, Gerald |e verfasserin |4 aut | |
| 700 | 1 | |a Plamondon, Stephanie |e verfasserin |4 aut | |
| 700 | 1 | |a Rodrigue, Xavier |e verfasserin |4 aut | |
| 700 | 1 | |a Schellenberg, Kerri |e verfasserin |4 aut | |
| 700 | 1 | |a Shoesmith, Christen |e verfasserin |4 aut | |
| 700 | 1 | |a Stables, Christine |e verfasserin |4 aut | |
| 700 | 1 | |a Taillon, Monique |e verfasserin |4 aut | |
| 700 | 1 | |a Warman-Chardon, Jodi |e verfasserin |4 aut | |
| 700 | 1 | |a Korngut, Lawrence |e verfasserin |4 aut | |
| 700 | 1 | |a O'Connell, Colleen |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of neuromuscular diseases |d 2014 |g 8(2021), 4 vom: 17., Seite 579-588 |w (DE-627)NLM246466057 |x 2214-3599 |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2021 |g number:4 |g day:17 |g pages:579-588 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3233/JND-200617 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2021 |e 4 |b 17 |h 579-588 | ||